Myriad Genetics (MYGN) Total Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Total Current Liabilities data on file, last reported at $130.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $130.2 million, down 13.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.2 million (down 13.83% YoY), and the FY2025 annual result was $133.8 million, down 18.46% from the prior year.
• Total Current Liabilities retreated to $130.2 million in Q1 2026 per MYGN's latest filing, from $133.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $221.1 million in Q2 2023 and troughed at $119.7 million in Q2 2022.
• A 5-year average of $156.4 million and a median of $148.9 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 55.83% in 2022, then surged 84.71% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $137.2 million in 2022, then gained by 13.63% to $155.9 million in 2023, then rose by 5.26% to $164.1 million in 2024, then dropped by 18.46% to $133.8 million in 2025, then decreased by 2.69% to $130.2 million in 2026.
• Business Quant data shows MYGN's Total Current Liabilities at $130.2 million in Q1 2026, $133.8 million in Q4 2025, and $148.0 million in Q3 2025.